We demonstrated that NDRG2 inhibition promoted the angiogenesis in HCC cell lines through VEGFA, and NDRG2 merits further investigation as a promising gene therapy target to treat HCC. This evidence concerns the gene NDRG2 and hepatocellular carcinoma.